Resmetirom-Reference-Cited by-同舟云学术

Resmetirom

Published:2024-09-05 Issue: Volume: Page:
ISSN:0018-5787
Container-title:Hospital Pharmacy
language:en
Short-container-title:Hosp Pharm

Author:

Levien Terri L.¹^ORCID,Baker Danial E.²^ORCID

Affiliation:

1. Pharmacotherapy Department, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, USA

2. College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, USA

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy and Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433.

Publisher

SAGE Publications

Link

https://journals.sagepub.com/doi/pdf/10.1177/00185787241278571

Reference19 articles.

1. Rezdiffra (resmetirom) [prescribing information]. West Conshohocken, PA: Madrigal Pharmaceuticals Inc; 2024.

2. Nikolov NP. NDA approval letter: Rezdiffra (resmetirom) (NDA 217785). Food and Drug Administration. Updated 2024. Accessed May 8, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/217785Orig1s000ltr.pdf

3. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease

4. American Association for the Study of Liver Diseases. Multinational Liver Societies announce new “fatty” liver disease nomenclature that is affirmative and non-stigmatizing. AASLD website. Updated June 24, 2023. Accessed May 8, 2024. https://www.aasld.org/news/multinational-liver-societies-announce-new-fatty-liver-disease-nomenclature-affirmative-and

5. A multisociety Delphi consensus statement on new fatty liver disease nomenclature